Vitrakvi for NTRK gene fusion-positive solid tumors
Quick answer: Vitrakvi is used for NTRK gene fusion-positive solid tumors as part of a trk (tropomyosin receptor kinase) inhibitor treatment regimen. Larotrectinib selectively inhibits TRKA, TRKB, and TRKC kinases, blocking oncogenic signaling from NTRK gene fusions The specific dosing for NTRK gene fusion-positive solid tumors is determined by your prescriber based on individual factors.
Why is Vitrakvi used for NTRK gene fusion-positive solid tumors?
Vitrakvi belongs to the TRK (tropomyosin receptor kinase) inhibitor class. Larotrectinib selectively inhibits TRKA, TRKB, and TRKC kinases, blocking oncogenic signaling from NTRK gene fusions This action makes it useful for treating or managing NTRK gene fusion-positive solid tumors in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Vitrakvi is the right choice for a specific patient depends on the type and severity of NTRK gene fusion-positive solid tumors, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for NTRK gene fusion-positive solid tumors
Common adult dosing range: 100 mg twice daily (adults); weight-based dosing in pediatrics. The actual dose for NTRK gene fusion-positive solid tumors depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Vitrakvi medicine page.
What to expect
Vitrakvi treatment for NTRK gene fusion-positive solid tumors typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on NTRK gene fusion-positive solid tumors
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Vitrakvi is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all TRK (tropomyosin receptor kinase) inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Vitrakvi
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Vitrakvi full prescribing information · All TRK (tropomyosin receptor kinase) inhibitor alternatives
Frequently asked questions
How effective is Vitrakvi for NTRK gene fusion-positive solid tumors?
Effectiveness varies by individual response, dose, and severity. Vitrakvi is one of several treatment options for NTRK gene fusion-positive solid tumors, supported by clinical evidence within the trk (tropomyosin receptor kinase) inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Vitrakvi for NTRK gene fusion-positive solid tumors?
Treatment duration depends on the nature of NTRK gene fusion-positive solid tumors — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Vitrakvi when used for NTRK gene fusion-positive solid tumors?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Vitrakvi for NTRK gene fusion-positive solid tumors?
Yes. Multiple medicines and non-drug options exist for NTRK gene fusion-positive solid tumors. Alternatives within the trk (tropomyosin receptor kinase) inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.